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Abstract
Objective Owing to lower mean uric acid excretion in women compared with men, uricosuric agents
might be preferred in women over xanthine oxidase (XO) inhibitors. We therefore investigated the dif-
ferences in response to two urate-lowering therapies (ULTs) with different modes of action within and
between sexes.
Methods This retrospective cohort study included patients with a clinical diagnosis of gout who
started allopurinol and/or benzbromarone. The successful response to ULT, defined as reaching a
serum uric acid (sUA) target of <0.36 mmol/l within 6 months after commencing ULT, was compared
between allopurinol and benzbromarone in women and men. Effect modification by sex on differences
in response was evaluated.
Results Allopurinol was started in 255 women and 1045 men, and benzbromarone in 60 women and
205 men. After 6 months, the proportions of women reaching the sUA target were 58.4% and 66.7%
for allopurinol and benzbromarone, respectively (difference, 8%; 95% CI: 22%, 5%). The respective
proportions in men were 61.0% and 75.6%, respectively (difference, 15%; 95% CI: 21%, 8%).
Corrected for confounding, the odds ratio (OR) of reaching the target on benzbromarone vs allopurinol
within women was 0.91 (95% CI: 0.47, 1.75), and within men 1.55 (95% CI: 1.04, 2.32). Corrected for
confounding, sex was not an effect modifier of the difference in allopurinol and benzbromarone re-
sponse (OR, 0.59; 95% CI: 0.28, 1.24).
Conclusion This study did not demonstrate between-sex differences regarding the response to either
a uricosuric agent or an XO inhibitor, negating different treatment choices by sex.
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Introduction
Gout is a preferential male disease, with a male-to-
female prevalence ratio of 3–4:1 [1]. Given this
distribution, less is known about gout in women, al-
though the incidence of gout in women has doubled
over the past two decades [2]. In recent years, the at-
tention on gout in women has increased. Studies show
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that the clinical manifestation of gout is different be-
tween women and men. For example, gout occurs in
women at an older age and is more frequently accom-
panied by co-morbidities, and women with gout use diu-
retics more frequently [3–5]. To our knowledge, there
are few data on a possible difference in the response to
urate-lowering therapy (ULT) between women and men.
Medication studies mostly include men, and no separate
data for women have been published, which precludes
subgroup analyses [6, 7]. However, this is a subject of
interest, because women and men differ on many levels,
such as lifestyle and biological processes, which could
influence the response to medication [8, 9].
An important difference is that women with gout seem
to have a lower mean uric acid excretion in comparison
to men with gout [10–12]. Also, in a large cohort of
patients without gout, who suffered from renal stones,
female patients showed significantly lower uric acid ex-
cretion compared with male patients [13]. This, possibly
more common, renal underexcretion of uric acid in
women with gout leads to two hypotheses regarding the
response to ULT. Firstly, there might be a better re-
sponse to a uricosuric agent (benzbromarone) compared
with a xanthine oxidase (XO) inhibitor (allopurinol) in fe-
male patients. Secondly, a relatively better response to
a uricosuric agent compared with an XO inhibitor might
be expected in female gout patients compared with
male gout patients.
Therefore, in this retrospective cohort study in sec-
ondary rheumatology care, we investigated the differen-
ces within and between sexes in the response to two
ULTs with different modes of action.
Methods
Study design
A retrospective cohort study was conducted in two
rheumatology clinics, the Sint Maartenskliniek Nijmegen
and Rijnstate Hospital Arnhem, The Netherlands. Data
on patient, disease and treatment characteristics were
collected from electronic health records. Approval from
the local ethics committee (Commissie Mensgebonden
Onderzoek region Arnhem-Nijmegen, 2018-4692) was
obtained. Patient informed consent was sought accord-
ing to Dutch law and the local rules of each participating
centre.
Participants
Patients, 18 years of age, with a clinical diagnosis of
gout (according to 2015 ACR/EULAR gout classification
criteria and/or clinical diagnosis by a rheumatologist
[14]) who had a minimum follow-up of 6 months between
January 2010 and September 2018, were ULT naive and
started allopurinol and/or benzbromarone during follow-
up were included in this cohort. ULT-naive patients were
selected to create a clear starting point. Given that allo-
purinol is the first-choice medication in the participating
hospitals, patients who used benzbromarone were often
switching from allopurinol or adding benzbromarone to
allopurinol during follow-up. If a patient had a treatment
period on both ULTs, both periods were included in the
study. A treatment period was defined from the start of
ULT until discontinuation or the end of follow-up (owing
to either being lost to follow-up or the study end).
Patients without any serum uric acid (sUA) measure-
ments after initiation of ULT were excluded.
Outcome measures
At baseline (commencement of the ULT treatment pe-
riod, either allopurinol or benzbromarone), patient and
disease characteristics were assessed. To measure the
difference in response, a successful response to ULT
was defined as reaching an sUA target of <0.36 mmol/l
[15] within 6 months after start of ULT. Secondary out-
comes were the time to reach the sUA target at any
time during follow-up after the start of ULT, and the ULT
dose at the time of reaching the sUA target.
Statistical analyses
No formal sample size calculation was made because a
convenient sample was used. All comparisons were
made between sexes and between allopurinol and benz-
bromarone. Baseline differences were, depending on
distribution, evaluated using Student’s two-sample t test
or the Mann–Whitney U test for continuous variables,
and the v2 test or Fisher’s exact test for categorical vari-
ables. The primary outcome for a successful response
to ULT treatment was presented as a proportion, the dif-
ference in proportions and 95% CI, evaluated by the
two-sample proportion z test. Using logistic regression,
after univariate analysis of baseline characteristics, the
multivariate model included correction for the confound-
ers sUA baseline levels, baseline estimated glomerular
filtration rate (eGFR) level and use of diuretics. Effect
modification of sex on between-drug response differen-
ces was analysed using an interaction term, sex*ULT.
Time to reach the target (any time during follow-up) was
analysed by Cox proportional hazard modelling, with
correction for sUA baseline levels. Here also, the inter-
action term for sex*ULT was tested for significance.
Furthermore, the model included an interaction term for
time*ULT to meet the proportional hazard assumption of
stable hazard rate (HR) over time, with time being di-
vided into the first 120 days after initiation of ULT and
the period after 120 days, based on HR distribution over
time. Finally, the ULT dose at the moment of reaching
the target was evaluated by linear regression corrected
for sUA baseline levels, baseline eGFR levels and age.
All analyses were done using cluster variance analyses
to account for interdependence between groups, be-
cause patients could be included in both the allopurinol
and benzbromarone treatment groups. Analyses were
conducted using STATA/IC v.13.1 (StataCorp, College
Station, TX, USA) and using complete case analysis.

















In this cohort, 1300 and 265 patient treatment periods
were included in the allopurinol and benzbromarone
group, respectively. Of the patients who started benz-
bromarone during follow-up, 251 patients did so in addi-
tion to allopurinol (n¼91) or switched from allopurinol
(n¼160), whereas 14 patients were naive starters.
Clinical characteristics at time of start of ULT are de-
scribed in Table 1. Women in both ULT treatment
groups had a significantly older mean age, more co-
morbidities, more frequent use of diuretics and higher
baseline sUA, compared with men. Both women and
men had a lower baseline level of sUA at the start of
benzbromarone treatment compared with the baseline
level before the start of allopurinol. Also, both women
and men treated with benzbromarone had a lower eGFR
compared with allopurinol users.
Successful response to ULT
Within 6 months after commencement of ULT, the
proportions of women who had reached the target
sUA were 58.4% and 66.7% for allopurinol and benz-
bromarone, respectively (difference, 8%; 95% CI:
22%, 5%). The proportions in men were 61.0% and
76.1% in allopurinol and benzbromarone users, re-
spectively (difference, 15%; 95% CI: 22%, 9%).
The corrected odds ratio (OR) of response to benz-
bromarone vs allopurinol within women was 0.91
(95% CI: 0.47, 1.75), and within men 1.61 (95% CI:
1.08, 2.41). The corrected OR of response to allopuri-
nol in women compared with men was 1.38 (95% CI:
0.95, 2.02), and the OR for benzbromarone response
for women compared with men was 0.79 (95% CI:
0.40, 1.58). Corrected for confounding, sex was not
an effect modifier of the difference in allopurinol and
benzbromarone response (OR 0.57; 95% CI: 0.27,
1.20).











Age, years, median (IQR) 74.9 (67.3–81.6) 63.7 (54.4–72.4) <0.001 75.8 (67.5–81.9) 66.3 (57.6–75.5) <0.001
Current alcohol use, n (%) 88 (34.5) 696 (66.7) <0.001 18 (30) 133 (64.9) <0.001
Co-morbidities, n (%)
Hypertension 176 (69.0) 496 (47.5) <0.001 43 (71.7) 104 (50.7) 0.004
Renal impairment 95 (37.3) 195(18.7) <0.001 25 (41.7) 48 (23.4) 0.005
Diabetes mellitus 93 (36.5) 204 (19.5) <0.001 24 (40) 45 (22.0) 0.009
Diuretics use, n (%) 169 (66.3) 403 (38.6) <0.001 45 (75) 99 (48.3) <0.001
Renal function, eGFR, ml/
min/1.73 m2, median (IQR)
46 (34–60) 70 (57–87) <0.001 38.5 (31.5–50.5) 65.5 (46.5–82) <0.001
History or presence of tophi,
n (%)
97 (38.0) 276 (26.4) <0.001 29 (48.3) 75 (36.6) 0.101
Erosive, n (%) 41 (16.1) 188 (18.0) 0.472 10 (16.7) 48 (23.4) 0.266
Crystal-proven gout, n (%) 190 (74.5) 734 (70.2) 0.177 46 (76.7) 144 (70.2) 0.331
Number of joints involvedb,
%
0.448 0.477
Monoarthritis 42 (16.5) 202 (19.3) – 9 (15) 37 (18.1) –
Oligoarthritis 144 (56.5) 546 (52.3) – 33 (55) 94 (45.9) –
Polyarthritis 67 (26.3) 282 (27) – 18 (30) 73 (35.6) –
Baseline serum uric acid,
mmol/l, mean (S.D.)
0.56 (0.12) 0.52 (0.10) <0.001 0.48 (0.14) 0.46 (0.13) 0.289
Starting dose, mg/day,
median (IQR)
100 (100–100) 100 (100–100) <0.001 50 (50–100) 100 (50–100) 0.147
Follow-up time, days,
median (IQR)
371 (163–657) 379 (194–652) 0.506 295.5 (70.5–614.5) 270 (95–565) 0.996
Allopurinol dose at time of
switch to benzbromarone,
mg/day
N/A N/A N/A 173.61 221.54 0.686c
Allopurinol dose at time of
adding benzbromarone,
mg/day
N/A N/A N/A 216.67 334.29 0.097c
aThe P-values for categorical variables were calculated by v2 analysis; for continuous variables, the appropriate (non-)para-
metric analysis was used, based on Gaussian distribution. bMissing data in some patients. cAfter correction for baseline
serum uric acid, renal function and age. eGFR: estimated glomerular filtration rate; IQR: interquartile range; N/A: not
assessed.
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Time to reach target 0.36 mmol/l (any time during
follow-up)
Figure 1 shows the Kaplan–Meier curves for time to
reach target. During the first 120 day period, both women
and men using benzbromarone reached the target sUA
faster compared with using allopurinol (for women, HR
2.74; 95% CI: 1.70, 4.43; and for men, HR 2.78; 95% CI:
2.16, 3.59). The time to reach the target sUA was not sig-
nificantly different in women compared with men for both
allopurinol and benzbromarone: HR 0.95 (95% CI: 0.81,
1.11) and HR 0.93 (95% CI: 0.57, 1.52), respectively.
For the period after 120 days, for both women and
men the HRs were inversely lower for benzbromarone
compared with allopurinol: HR 0.57 (95% CI: 0.34, 1.06)
and HR 0.57 (95% CI: 0.38, 0.86) for women and men,
respectively. Again, corrected for confounding, sex was
not an effect modifier of the difference in the time to
reach the target sUA for allopurinol and benzbromarone
during follow-up (HR 0.98; 95% CI: 0.60, 1.61).
ULT dose at target serum uric acid <0.36 mmol/l
The mean dose of allopurinol at the time of reaching the
target sUA was lower in women compared with men,
216 mg and 271 mg, respectively (difference 55 mg;
95% CI: 73, 37). After correction, this difference
remained statistically significant, at 45 mg (95% CI:
67, 23). The mean dose of benzbromarone at the tar-
get sUA was similar for women and men: 86 mg and
88 mg, respectively (difference 2 mg; 95% CI: 15,
11). After correction, this difference was 4 mg (95% CI:
9, 18). For the subset of patients using benzbromarone
in addition to allopurinol, mean doses were similar for
women and men at the time of reaching the target sUA.
Discussion
Our results show that, although women have lower urate
excretion than men [10, 11], this does not translate into
relevant differences between women and men in
response rates to an XO inhibitor or a uricosuric drug.
Therefore, the choice of urate-lowering drug does not
have to be based on the supposed sex differences.
Three interesting additional findings were observed.
Firstly, the time to reach the sUA target for benzbromar-
one compared with allopurinol was significantly shorter.
Secondly, more men on benzbromarone reached the
sUA target within 6 months than on allopurinol. Thirdly,
women reached the sUA target at a lower mean allopuri-
nol dose than men.
Starting with the first observation, there are several
explanations for the more swift response to benzbro-
marone. Firstly, this might be caused by the lower base-
line sUA before the start of benzbromarone, because
this treatment is often given as an add-on to allopurinol.
However, this was accounted for in the analyses. Also,
benzbromarone is often started at a higher dose relative
to its maximum dose than allopurinol. Another reason
for this finding might be that benzbromarone is a more
potent drug with regard to sUA lowering. Renal handling
of uric acid plays a key role in the pathophysiology of
gout in most patients [16]. Given that benzbromarone
inhibits uric acid reabsorption, it provides a more logical
pharmacological approach to hyperuricaemia in most
patients. When using this drug in clinical practice, this
faster response should be taken into account when us-
ing this drug in a treatment strategy. The second finding
follows the same reasoning as the first, with the statisti-
cally significant difference possibly found only in men
because of the smaller sample of women in our cohort.
Regarding the third finding, the lower effective allopu-
rinol dose in women might be caused by residual con-
founding; for example, BMI was not corrected owing to
a large number of missing values. Another reason might
be different pharmacokinetic or pharmacodynamic
effects in women compared with men. Unfortunately, re-
liable subgroup analyses by sex are very rare in existing
allopurinol studies because the proportion of women is
often 10% or less. In a previous study looking at the ef-
ficacy of febuxostat and allopurinol in women using data
FIG. 1 Kaplan–Meier curve for time to reach the target at any time during follow-up
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from three randomized controlled trials, only 226 women
of the >4000 patients were included [7].
Strengths of this study include a relatively large popula-
tion of both sexes, especially women, and comparison be-
tween allopurinol and benzbromarone, a drug for which
data are relatively scarce. Although the latter might also
limit generalizability, our goal was to make a comparison
between an XO inhibitor with a uricosuric drug in light of
the lower sUA excretion in women. Although benzbromar-
one is not used worldwide, newer uricosuric drugs have
been developed and marketed recently. Considering the
same working mechanism, we hypothesize that other uri-
cosuric drugs might have similar effects to benzbromar-
one, making this a comparison of interest. Our cohort is
considered to be a good representation of gout patients in
secondary rheumatology care because the male-to-female
ratio, patient and disease characteristics and the differen-
ces in these characteristics between women and men are
comparable to previous studies in secondary care [3–5].
Limitations of our study are, firstly, the retrospective de-
sign, mostly attributable to incomplete outcome assess-
ment. This is also the reason why we chose to use the
sUA target instead of flare incidence, because the former
is better assessed in this study. Also, nearly all patients
who used benzbromarone previously failed allopurinol,
and this might result in biased efficacy estimates for benz-
bromarone and for the comparison between allopurinol
and benzbromarone. However, this should not hamper
comparison between sexes, also because we used cluster
variance analyses to account for interdependence.
In conclusion, this study did not demonstrate
between-sex differences regarding the response to ei-
ther a uricosuric agent or an XO inhibitor, negating dif-
ferent treatment choices by sex.
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10 Puig JG, Michán AD, Jiménez ML et al. Female gout.
Clinical spectrum and uric acid metabolism. Arch Intern
Med 1991;151:726–32.
11 Park YB, Park YS, Song J et al. Clinical manifestations
of Korean female gouty patients. Clin Rheumatol 2000;
19:142–6.
12 te Kampe R, van Durme C, Janssen M, Boonen A,
Jansen T. AB1043 The clinical profile of gout
significantly differs between male and female. Ann
Rheum Dis 2018;77(Suppl 2):1637.
10.1136/annrheumdis-2018-eular.7251
13 Walker V, Stansbridge EM, Griffin DG. Demography and
biochemistry of 2800 patients from a renal stones clinic.
Ann Clin Biochem 2013;50:127–39.
14 Neogi T, Jansen TL, Dalbeth N et al. 2015 Gout
classification criteria: an American College of
Rheumatology/European League Against
Rheumatism collaborative initiative. Ann Rheum Dis
2015;74:1789–98.
15 Richette P, Doherty M, Pascual E et al. 2016 updated
EULAR evidence-based recommendations for
the management of gout. Ann Rheum Dis 2017;76:
29–42.
16 Benn CL, Dua P, Gurrell R et al. Physiology of
hyperuricemia and urate-lowering treatments. Front Med
(Lausanne) 2018;5:160.













trecht user on 04 M
ay 2021
